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Introduction: Influenza vaccine is recommended for 
the entire population in Israel. We assessed influenza 
vaccine effectiveness (VE) for the 2014/15 and 2015/16 
seasons in Israel, for the first time. Methods: Combined 
nose and throat swab specimens were collected from 
patients with influenza-like illness (ILI) presenting to 
sentinel primary care clinics and tested for influenza 
virus by RT-PCR. VE of the trivalent inactivated vaccine 
(TIV) was assessed using test-negative case–con-
trol design. Results: During the 2014/15 season 1,142 
samples were collected; 327 (28.6%) were positive 
for influenza, 83.8% A(H3N2), 5.8% A(H1N1)pdm09, 
9.2% B and 1.2% A un-subtyped. Adjusted VE against 
all influenza viruses for this influenza season was 
−4.8% (95% confidence interval (CI): −54.8 to 29.0) 
and against influenza A(H3N2), it was −15.8% (95% 
CI: −72.8 to 22.4). For the 2015/16 season, 1,919 sam-
ples were collected; 853 (44.4%) were positive for 
influenza, 43.5% A(H1N1)pdm09, 57% B, 0.7% A(H3N2) 
and 11 samples positive for both A(H1N1)pdm09 and B. 
Adjusted VE against all influenza viruses for this influ-
enza season was 8.8% (95% CI: −25.1 to 33.5), against 
influenza A(H1N1)pdm09, it was 32.3% (95% CI: (−4.3 
to 56.1) and against influenza B, it was −2.2% (95% 
CI: (−47.0 to 29.0).  Conclusions:  Using samples from 
patients with ILI visiting sentinel clinics in Israel, we 
demonstrated the feasibility of influenza VE estima-
tion in Israel.
Introduction 
Influenza virus infection causes morbidity and mortal-
ity worldwide every year [1]. The most effective meas-
ure of preventing influenza is the influenza vaccine. 
However, influenza vaccine effectiveness (VE) can vary 
considerably, both by season [2], and geographic loca-
tion [2,3].
Israel is a country of 8.5 million people, with a 
Mediterranean and arid climate, located in the west-
ernmost part of Asia. In Israel, influenza activity is 
seasonal, usually occurring from December through 
March [4] in patterns similar to those of Europe and 
those in neighbouring Jordan [5] and Egypt [6]. The 
outpatient sentinel influenza surveillance system was 
established in the 1996/97 season and has been con-
ducted through primary care clinics throughout Israel. 
The sentinel clinics are located in all seven districts 
of Israel and are staffed by paediatricians, internists 
and family physicians. During the 2014/15 and 2015/16 
influenza seasons, 23 and 26 sentinel clinics, respec-
tively, participated in influenza surveillance. Israel’s 
Ministry of Health recommends influenza vaccination 
for the entire population over the age of 6 months [7]. 
The trivalent inactivated vaccine (TIV), the quadriva-
lent inactivated vaccine (QIV) and live attenuated influ-
enza vaccine (LAIV) are all registered for use in Israel. 
The inactivated vaccines against seasonal influenza 
are offered free of charge to all residents through clin-
ics of the four national ‘sick fund’ organisations which 
are widely spread throughout the country and are simi-
lar to health maintenance organisations in the United 
States (US). TIV is the most widely used influenza vac-
cine in Israel.
In this study we evaluated, for the first time, VE against 
medically attended laboratory-confirmed influenza-like 
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illness (ILI) in the community in Israel using our sen-
tinel surveillance system. The predominant influenza 
strain in the 2014/15 season was a drifted influenza 
A(H3N2). Influenza A(H1N1)pdm2009 and influenza B 
co-circulated in Israel during the 2015/16 season. The 
overall influenza vaccination coverage in Israel dur-
ing the 2014/15 and 2015/16 seasons was ca 21%. The 
vaccine coverage was ca 65%, 25% and 40% among 
individuals age 65 years of age and over, infants and 
children 6 months to 5 years, and individuals less 
than 65 years of age with chronic medical conditions, 
respectively [8,9].
We used the test-negative case–control design, a com-
monly used method for estimating influenza VE in 
studies that utilise sentinel surveillance systems [10].
Methods 
Study period and population
Influenza surveillance periods lasted in Israel from 
28 September 2014 until 18 April 2015, and from 27 
September 2015 until 16 April 2016. During these peri-
ods, sentinel clinic providers obtained combined nasal 
and throat swabs [11] from a convenience sample of 
patients meeting the ILI case definition. The kits of 
combined nasal and throat swabs were provided to all 
sentinel clinics by the Israel Center for Disease Control. 
ILI was defined as a temperature of 37.8˚C and over, 
accompanied by one or more of the following symp-
toms: coryza, sore throat, cough, and muscle ache [12]. 
Discretion was given to physicians to include other 
signs or symptoms considered relevant. Sentinel clin-
ics were asked to send up to ten samples per week.
Figure 1
Weekly distribution of influenza-positive samples from outpatient sentinel clinics, Israel, influenza seasons 2014/15 and 
2015/16
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For each patient a questionnaire with demographic, 
epidemiologic and clinical data was completed by sen-
tinel medical staff. The data included date of birth, 
sex, date of disease onset, date of sample collection 
and influenza vaccine status for the evaluated season, 
including the date of vaccination and the type of vac-
cine used. For children less than 9 years of age, pro-
viders recorded whether a second dose was needed 
(for those receiving the influenza vaccine for the first 
time) and the date of the second dose, if indicated. 
Information regarding chronic medical conditions plac-
ing patients at risk for influenza-related complications 
was available for the 2015/16 season.
Molecular identification of influenza viruses in 
samples obtained from sentinel patients with 
influenza-like illness
The combined nasal and throat samples from senti-
nel ILI patients were kept at 4˚C in the upright position 
until transport. Samples were transported once a week 
Figure 2
Flowchart of influenza-like illness patients from sentinel primary care clinics, Israel, influenza seasons 2014/15 and 2015/16 
(n = 1,142 and 1,919, respectively)
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F. Date of onset unknown (n = 8)
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J.   B+C (n = 1)
K.  C+D (n = 1)
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F.   Type of vaccine unknown (n = 20)
G.  Date of onset unknown (n = 25)
H.  Missing sample date (n = 2)
I.    Laboratory results unavailable (n = 1)
J.    A+B (n = 4)
K.   B+C (n = 1)
L.    E+H (n = 1)
Individuals swabbed for influenza
(n = 1,919)
Individuals swabbed for influenza
(n = 1,142)
A. 2014/15 influenza season B. 2015/16 influenza season
Control
(n = 699)
Cases
(n = 316)
Control
(n = 698)
Cases
(n = 307)
Exclusion of LAIV recipients 
(n = 10)
Individuals eligible for VE analysis 
(n = 1,005)
Control
(n = 882)
Cases
(n = 788)
Control
(n = 873)
Cases
(n = 785)
Exclusion of QIV recipients 
(n = 12)
Individuals eligible for VE analysis 
(n = 1,658)
LAIV: live attenuated influenza vaccine; QIV: quadrivalent inactivated influenza vaccine; VE: vaccine effectiveness.
4 www.eurosurveillance.org
in cooling containers, by car, to the Central Virology 
Laboratory of the Israel Ministry of Health. The sam-
ples were tested for influenza by real-time RT-PCR. 
The viral genome was extracted from the samples 
during the 2014/15 season using NucliSENS easyMAG 
(BioMerieux, Marcy l’Etoile, France) and during the 
2015/16 season using the KingFisher Purification 
System (Thermo Fisher Scientific, Vantaa, Finland) and 
the NucleoMag RNA (Macherey-Nagel, Düren, Germany) 
RNA extraction kit. Influenza viruses were then tested 
by real-time RT-PCR using Applied Biosystems 7500 
Real-Time PCR system (Foster City, CA, US) and the 
Ambion Ag-Path Master Mix (Life Technologies, US) 
and TaqMan Chemistry (Foster City, CA, US) [13-16].
A subset of influenza A(H3N2) circulating in Israel 
during the 2014/15 season, and subsets of influenza 
A(H1N1)pdm09 and B circulating in Israel during the 
2015/16 season underwent nt sequencing of the hae-
magglutinin (HA) gene. Sequenced viruses were from 
samples collected at various stages of each influenza 
season. Influenza HA gene-specific primers were used 
to partially amplify the influenza A and influenza B 
HA genes, as previously described according to World 
Health Organization (WHO) protocols [17].
Amplified PCR products were sequenced using ABI 
PRISM Dye Deoxy Terminator cycle sequencing kit 
(Applied Biosystems, Foster City, CA, US). Reaction 
mixtures were then analysed using ABI 3500 DNA 
Genetic Analyzer (Applied Biosystems, Foster City, 
CA, USA). Alignment and comparison of nt sequences 
were carried out using the Sequencher software ver-
sion 5.4 (Gencodes Corporation, Ann Arbor, MI, US). HA 
sequences of reference strains used for phylogenetic 
analysis were obtained from the EpiFlu database of the 
Global Initiative on Sharing All Influenza Data (plat-
form.gisaid.org).
Study design
VE against influenza was assessed for individuals 6 
months of age and over who received the TIV, using 
the test-negative case–control design [18,19]. VE was 
derived as (1−odds ratio (OR)) × 100, expressed as a 
Table 1
Characteristics of samples from influenza-like illness patients eligible for vaccine effectiveness analysis, Israel, influenza 
season 2014/15 (n = 1,005)
Characteristics
Controls 
(n = 698)
Influenza types and subtypes of cases (n = 307)
Total 
(n = 1,005) p valuecTotal A (n = 277)
A(H1N1)pdm09 
(n = 17)
A(H3N2) 
(n = 257)
A(unsubtyped) 
(n = 3) B (n = 30)
n (%)a n (%)a n (%)a n (%)a n (%)a n (%)a n (%)b
Age groups
6 months–17 years 413 (70.2) 165 (28.1) 7 (1.2) 157 (26.7) 1 (0.2) 10 (1.7) 588 (58.5)
0.8318–44 years 193 (68.0)
76 
(26.8) 7 (2.5) 68 (23.9) 1 (0.4) 15 (5.3) 284 (28.2)
45–64 years 59 (66.3) 27 (30.3) 2 (2.2) 24 (27.0) 1 (1.1) 3 (3.4) 89 (8.9)
≥ 65 years 33 (75.0) 9 (20.5) 1 (2.3) 8 (18.2) 0 (0) 2 (4.5) 44 (4.4)
Sex
Male 360 (69.4) 142 (27.3) 8 (1.5) 133 (25.6) 1 (0.2) 17 (3.3) 519 (51.6)
0.95
Female 338 (69.6) 135 (27.8) 9 (1.8) 124 (25.5) 2 (0.4) 13 (2.7) 486 (48.4)
Interval between symptom onset and swab
0–1 days 365 (71.0) 134 (26.1) 7 (1.4) 126 (24.5) 1 (0.2) 15 (2.9) 514 (51.1)
0.532–4 days 299 (67.0) 133 (29.8) 9 (2.0) 122 (27.3) 2 (0.4) 14 (3.1) 446 (44.4)
5–7 days 34 (75.6) 10 (22.2) 1 (2.2) 9 (20) 0 (0) 1 (2.2) 45 (4.5)
Vaccination statusd
Unvaccinated 577 (69.9) 222 (26.9) 15 (1.8) 204 (24.7) 3 (0.4) 26 (3.1) 825 (82.0)
0.47
Vaccinated (TIV) 121 (67.2) 55 (30.6) 2 (1.1) 53 (29.4) 0 (0) 4 (2.2) 180 (17.9)
TIV: trivalent inactivated vaccine.
a Percentage based on total of each row.
b Percentage based on the total of 1,005.
c Analysis performed for influenza positive (cases) vs negative (controls).
d Individuals receiving live attenuated influenza vaccine (LAIV) (n=10) were excluded from the table and analysis.
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percentage. VE was estimated for influenza A and B 
together and for the specific influenza subtypes, for 
each of the two seasons. VE was not calculated for cer-
tain influenza types and subtypes if the total number 
of positive samples for the type or subtype was very 
low, not allowing at least 5 samples in each cell of the 
contingency table used for OR calculation. Individuals 
were considered vaccinated if they received the influ-
enza vaccine 14 days or more before disease onset. 
For children between the ages of 6 months and 9 years 
receiving the influenza vaccine for the first time, only 
those receiving two doses, with the second dose given 
14 days or more before illness, were included in the 
analysis. Individuals whose samples were taken more 
than 7 days after of onset of symptoms were excluded 
from analysis. Because relatively few individuals 
received LAIV or QIV during the two influenza seasons, 
we estimated VE for TIV only.
Statistical analysis
Percentages were compared using the Mantel-Haenszel 
chi-squared test. OR for crude VE calculation was 
performed using a univariate logistic regression model 
with no covariates. We adjusted for age group, sex, 
calendar week of sample collection, days from disease 
onset to swab and underlying chronic medical condi-
tions (information regarding chronic conditions was 
available for the 2015/16 season only) using multivaria-
ble logistic regression. Sensitivity analysis was carried 
out to evaluate whether there was a difference between 
individuals who were swabbed on days 0–1 from symp-
tom onset and individuals who were swabbed on days 
2–7 from symptom onset. Statistical analyses were car-
ried out using SAS version 9.4 (SAS Institute, Cary, NC, 
US).
Ethical consideration
Sentinel influenza surveillance in Israel, including the 
testing component, is conducted in accordance with 
the Public Health Ordinance enacted in Israel and does 
not require informed consent. Molecular characterisa-
tion of influenza strains isolated from patients was 
approved by the ethics committee at the Sheba Medical 
Center (1967–15-SMC), Tel Hashomer, Israel.
Table 2
Characteristics of samples from influenza-like illness patients eligible for vaccine effectiveness analysis, Israel, influenza 
season 2015/16 (n = 1,658)
Characteristics
Controls 
(n = 873)
Influenza types and subtypes of cases (n = 785)
Total 
(n = 1,658) p 
valued
Total A 
(n = 348)a
A(H1N1)pdm09 
(n = 332)
A(H3N2) 
(n = 5)
A(H1N1)pdm09 + B 
(n = 11)
B 
(n = 448)a
n (%)b n (%)b n (%)b n (%)b n (%)b n (%)b n (%)c
Age groups
6 months–17 years 450 (55.2) 129 (15.8) 123 (15.1) 0 (0) 6 (0.7) 242 (29.7) 815 (49.2)
0.83
18–44 years 234 (45.0) 142 (27.3) 138 (26.5) 1 (0.2) 3 (0.6) 147 (28.3) 520 (31.4)
45–64 years 131 (58.5) 60 (26.8) 56 (25.0) 3 (1.3) 1 (0.4) 34 (15.2) 224 (13.5)
≥ 65 years 58 (58.6) 17 (17.2) 15 (15.1) 1 (1.0) 1 (1.0) 25 (25.2) 99 (6.0)
Sex
Male 434 (52.8) 178 (21.6) 169 (20.6) 3 (0.4) 6 (0.7) 216 (26.3) 822 (49.6)
0.91
Female 439 (52.5) 170 (20.3) 163 (19.5) 2 (0.2) 5 (0.6) 232 (27.8) 836 (50.4)
Chronic medical conditions
Yes 172 (60.6) 49 (17.2) 45 (15.8) 2 (0.7) 2 (0.7) 65 (22.9) 284 (17.1)
< 0.01No 696 (50.9) 298 (21.8) 286 (20.9) 3 (0.2) 9 (0.7) 382 (28.0) 1367 (82.4)
Missing 5 (71.4) 1 (14.3) 1 (14.3) 0 (0) 0 (0) 1 (14.3) 7 (0.4)
Interval between symptom onset and swab
0–1 days 386 (57.6) 132 (19.7) 124 (18.5) 0 (0) 8 (1.2) 160 (23.9) 670 (40.4)
< 0.012–4 days 421 (48.9) 188 (21.9) 182 (21.2) 3 (0.3) 3 (0.3) 254 (29.5) 860 (51.9)
5–7 days 66 (51.6) 28 (21.9) 26 (20.3) 2 (1.6) 0 (0) 34 (26.6) 128 (7.7)
Vaccination statuse
Unvaccinated 742 (52.4) 308 (21.7) 294 (20.8) 3 (0.2) 11 (0.8) 377 (26.6) 1416 (85.4)
0.62
Vaccinated (TIV) 131 (54.1) 40 (16.5) 38 (15.7) 2 (0.8) 0 (0) 71 (29.3) 242 (14.6)
TIV: trivalent inactivated vaccine.
a The 11 samples positive for influenza A(H1N1)pdm09 and influenza B are included in both the count of ‹Total A› column and the ‹B› column.
b Percentage based on total of each row.
c Percentage based on the total of 1,658.
d Analysis performed for influenza positive (cases) vs negative (controls).
e Individuals receiving quadrivalent inactivated influenza vaccine (QIV) (n=12) were excluded from the table and analysis.
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Results 
Influenza season and virus circulation
2014/15 influenza season
During the 2014/15 influenza surveillance season, 
1,142 samples were collected from ILI patients. A total 
of 327 (28.6%) samples were positive for influenza, of 
which 297 (90.8%) samples were positive for influenza 
A, and 30 (9.2%) were positive for influenza B. Of the 
297 influenza A samples, 274 (92.3%) were A(H3N2), 19 
(6.4%) were A(H1N1)pdm09, and 4 (1.3%) were un-sub-
typed (Figure 1A) [20]. Characterisation of 22 influenza 
B samples demonstrated that 21 samples belonged to 
the Yamagata lineage and 1 belonged to the Victoria 
lineage.
 
Molecular characterisation of a convenience sam-
ple of 22 influenza A(H3N2) viruses from community 
sentinel patients, showed that all belonged to the 
3C.2a clade, while the vaccine strain influenza A/
Texas/50/2012(H3N2) belonged to the 3C.1 clade. A 
detailed description and phylogenetic tree were previ-
ously reported [21].
2015/16 influenza season
Of the 1,919 samples that were collected from ILI 
patients during the 2015/16 influenza season, a total 
of 853 (44.5%) samples were positive for influenza, of 
which 377 (44.2%) samples were positive for influenza 
A, and 487 (57.1%) were positive for influenza B. Of the 
377 influenza A samples, 371 (98.4%) were A(H1N1)
pdm09, and 6 (1.6%) were A(H3N2) (Figure 1B) [4]. A 
total of 11 samples (1.3% of the positive influenza sam-
ples) were positive for both influenza A(H1N1)pdm09 
and influenza B [22].
Molecular characterisation of a convenience sample 
of 31 influenza A(H1N1)pdm09 viruses from commu-
nity sentinel patients, showed that 16 belonged to the 
6B.1 clade and 15 to the 6B.2 clade, while the vaccine 
strain A/California/07/2009(H1N1)pdm09 belonged to 
clade 1. Molecular characterisation of 452 Influenza 
B viruses demonstrated that 394 (87.2%) belonged to 
the Victoria lineage, and 58 (12.8%) belonged to the 
Yamagata lineage, while the B components of the tri-
valent vaccine, B/Phuket/3073/2013, belonged to the 
Yamagata lineage [22].
Study population
2014/15 influenza season
Of the 1,142 samples collected from patients with ILI, 
127 samples were excluded due to missing vaccination 
status or vaccination dates, missing day of symptom 
onset, sampling more than 7 days after onset of symp-
toms, receipt of influenza vaccine less than 14 days 
before disease onset, or because of partial vaccination 
(children less than 9 years old require two vaccine doses) 
(Figure 2). Of the 1,015 remaining ILI patients (316 cases 
and 699 controls), 10 received the LAIV (Figure 2); all 
10 were less than 13.5 years of age and excluded from 
the study. The remaining vaccinated patients received 
the trivalent injected egg-grown vaccine (split or inac-
tivated) containing an A/California/7/2009(H1N1)
pdm09-like virus, an A/Texas/50/2012(H3N2)-like virus 
and a B/Massachusetts/2/2012-like virus. The charac-
teristics of the 1,005 samples that were included in the 
assessment are presented in Table 1.
2015/16 influenza season
Of the 1,919 samples collected from ILI patients, a total 
of 249 samples were excluded due to missing vaccina-
tion status or vaccination dates, missing day of symp-
toms onset, sampling more than 7 days after onset of 
symptoms, receipt of influenza vaccine less than 14 
days before disease onset, partial vaccination (children 
less than 9 years old require two vaccine doses) and 
missing vaccine type (Figure 2). Of the 1,670 remaining 
ILI patients (788 cases and 882 controls), 12 received 
Table 3
Vaccine effectiveness estimates for trivalent inactivated vaccine based on influenza-positive and influenza-negative samples 
among cases and controls, Israel, influenza season 2014/15 (n =1,005)
Influenza 
type/subtype Age
Cases 
 
(n =307)
Controls 
 
(n =698)
Crude VE Adjusted VE
Vaccinated Unvaccinated Vaccinated Unvaccinated % (95% CI) % (95%CI)
A and B
All 59 248 121 577 −13.4 (−60.2 to 19.7) −4.8 (−54.8 to 29.0)a
6 months–17 years 24 151 68 345 19.4 (−33.4 to 51.2) 30.5 (−18.3 to 59.1)b
≥18 years 35 97 53 232 −58.0 (−157.4 to 3.1) −53.7 (−166.8 to 11.4)b
A(H3N2)
All 53 204 121 577 −23.9 (−77.6 to 13.6) −15.8 (−72.8 to 22.4)a
6 months–17 years 24 133 68 345 8.4 (−51.9 to 44.8) 22.7 (−31.7 to 54.6)b
≥ 18 years 29 71 53 232 −78.8 (−202.3 to −5.8) −75.7 (−216.3 to 2.4)b
VE: vaccine effectiveness.
a Adjusted for age group, sex, calendar week and time (days) from symptom onset to swab.
b Adjusted for sex, calendar week and time (days) from symptom onset to swab.
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the injectable quadrivalent egg-grown split virus vac-
cine (QIV) and were excluded from the study. No LAIV 
was available in Israel during the 2015/16 influenza 
season. The 242 vaccinated individuals received the tri-
valent injected egg-grown vaccine (split or inactivated) 
containing an A/California/7/2009(H1N1)pdm09-like 
virus, an A/Switzerland/9715293/2013(H3N2)-like virus 
and a B/Phuket/3073/2013-like virus. The characteris-
tics of the 1,658 samples eligible for VE analysis are 
detailed in Table 2.
Vaccine effectiveness estimates against 
influenza virus
2014/15 influenza season
For the 2014/15 season, adjusted TIV VE against influ-
enza A and B adjusted for age group, gender and calen-
dar week was −4.8% (95% CI: −54.8 to 29.0) (Table 3). 
The adjusted VE against the 2014/15 influenza A(H3N2) 
was −15.8% (95% CI: −72.8 to 22.4) (Table 3). We did 
not calculate VE for influenza A(H1N1)pdm09 or influ-
enza B in the 2014/15 season due to the small number 
of positive samples (17 and 30 samples, respectively).
2015/16 influenza season
The adjusted TIV VE against influenza A and B viruses 
for 2015/16 season for all ages was 8.8% (95% CI: 
−25.1 to 33.5) (Table 4). The adjusted TIV VE against the 
2015/16 influenza A(H1N1)pdm09 was 32.3% (95% CI: 
−4.3 to 56.1), and the adjusted VE against the 2015/16 
influenza B was −2.2% (95% CI: −47.0 to 29.0) (Table 
4). Since only five individuals were infected with influ-
enza A(H3N2), no VE analysis was performed for this 
subtype.
Sensitivity analysis
Sensitivity analysis demonstrated substantial differ-
ences in VE estimates between individuals who were 
swabbed on days 0–1 days vs 2–7 days from disease 
onset in the 2014/15 and the 2015/16 seasons (Table 
5).
Vaccine effectiveness estimates stratified by age
2014/15 influenza season
For the 2014/15 season, the adjusted TIV VE for influ-
enza A and B were 30.5% (95% CI: −18.3 to 59.1) for 
individuals less than 18 years of age, and −53.7% (95% 
CI: −166.8 to 11.4) for adults 18 years of age and over. 
The adjusted TIV VE against influenza A(H3N2) alone 
was 22.7% (95% CI: −31.7 to 54.6) for individuals less 
than 18 years of age, and −75.7% (95% CI: −216.3 to 
2.4) for adults 18 years and over (Table 3).
2015/16 influenza season
For the 2015/16 season, the adjusted TIV VE for indi-
viduals 18 years of age and over was 39.1% (95% CI: 
7.8 to 59.8) against any influenza, 56.5% (95% CI: 24.3 
to 75.0) against influenza A(H1N1)pdm09, and 26.5% 
(95% CI: −20.6 to 55.2) against influenza B (Table 4).
For individuals less than 18 years of age, the adjusted 
TIV VE was −25.0% (95% CI: −98.0 to 21.0), against 
any influenza, −8.1% (95% CI: −104 to 42.7) against 
A(H1N1)pdm09, and −25.0% (95% CI: –106.8 to 24.5) 
against influenza B (Table 4).
Table 4
Vaccine effectiveness estimates for trivalent inactivated vaccine based on influenza-positive and influenza-negative samples 
among cases and controls, Israel, influenza season 2015/16 (n = 1,658)
Influenza 
type/subtype Age
Cases 
 
(n = 785)
Controls 
 
(n = 873)
Crude VE Adjusted VE
Vaccinated Unvaccinated Vaccinated Unvaccinated % (95% CI) % (95%CI)
A and B
All 111 674 131 742 6.7 (−22.6 to 29.0) 8.8 (−25.1 to 33.5)a
6 months–17 years 55 310 44 406 −63.7 (−149.9 to −7.2) −25.0 (−98.0 to 21.0)b
≥ 18 years 56 364 87 336 40.6 (14.2 to 58.8) 39.1 (7.8 to 59.8)b
A(H1N1)
pdm09c
All 38 305 131 742 29.4 (−3.7 to 52.0) 32.3 (−4.3 to 56.1)a
6 months–17 years 17 112 44 406 −40.1 (−154.6 to 22.9) −8.1 (−104 to 42.7)b
≥ 18 years 21 193 87 336 58.0 (30.1 to 74.7) 56.5 (24.3 to 75.0)b
Bc
All 71 377 131 742 −6.7 (−46.1 to 22.1) −2.2 (−47.0 to 29.0)a
6 months–17 years 38 204 44 406 −71.9 (−173.8 to −7.9) −25.0 (−106.8 to 24.5)b
≥ 18 years 33 173 87 336 26.3 (−14.5 to 52.6) 26.5 (−20.6 to 55.2)b
a Adjusted for age group, sex, calendar week, underlying condition and time (days) from symptom onset to swab.
b Adjusted for sex, calendar week, underlying condition and time (days) from symptom onset to swab.
c The 11 samples positive for influenza A(H1N1)pdm09 and influenza B in the 2015/16 season are included in the analysis of influenza A(H1N1)
pdm09 and influenza B.
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Discussion
This was the first study in Israel to evaluate influenza 
VE in the community using the test-negative case–con-
trol design. In this study we evaluated two seasons 
with different circulation of influenza viruses. We found 
that in the 2014/15 season, which was characterised 
by the predominance of a drifted strain of influenza 
A(H3N2), the TIV was not effective. These findings are 
consistent with reported VE against community influ-
enza A(H3N2) from the UK [18,23], Canada [24], the 
US [25-27], Navarra, Spain [28] and Austria [29] in the 
same season.
These results are also consistent with the findings of an 
Israeli study demonstrating that sera from Israeli indi-
viduals vaccinated with the 2014/15 injected split virus 
vaccine had reduced ability to neutralise the drifted 
influenza A(H3N2) virus [21]. Although the 2014/15 
influenza vaccine was not effective against outpatient 
influenza A(H3N2) in our study, several studies dem-
onstrated a better VE against preventing influenza 
A(H3N2)-associated hospitalisations [30,31], reaching 
43% in one study [30].
For the 2015/16 influenza season, which was character-
ised by the co-dominance of influenza A(H1N1)pdm09 
and influenza B, VE estimates varied by virus and age 
group. The TIV was moderately effective against influ-
enza A(H1N1)pdm09 in adults over the age of 18 but not 
in those 6 months to 17 years of age. Low (and not sta-
tistically significant) TIV VE was demonstrated against 
influenza B in either age group.
Our TIV VE results against influenza A(H1N1)pdm09 in 
adults during the 2015/16 season are consistent with 
VE results of the inactivated vaccine against laboratory 
confirmed influenza A(H1N1)pdm09 in primary care 
setting in the US [32], Canada [33], European coun-
tries that are part of the Influenza Monitoring Vaccine 
Effectiveness in Europe (I-MOVE) [34] and the UK [35]. 
Likewise, the molecular characterisation results for 
influenza A(H1N1)pdm09 in Israel are consistent with 
other northern hemisphere results, showing that they 
belong to clades 6B.1 and 6B.2 [33,35,36].
Although most influenza B viruses detected in Israel 
during the 2015/16 season belonged to the Victoria 
lineage, the 2015/16 TIV contained only the Yamagata 
lineage. In contrast to the 2015/2016 influenza season, 
during the 2012/13 and 2013/14 influenza seasons, the 
Yamagata lineage predominated in Israel [37]. Little 
influenza B, mostly of the Yamagata lineage, circulated 
in Israel during the 2014/15 season. Thus, our low TIV 
VE results against influenza B may stem from a line-
age mismatch between the dominant influenza B virus 
and the 2015/16 TIV influenza B component, along with 
reduced exposure to the Victoria lineage in the previ-
ous three seasons.
Table 5
Sensitivity analysis of trivalent inactivated influenza vaccine effectiveness in preventing medically attended laboratory 
confirmed influenza, Israel, influenza seasons 2014/15 and 2015/16 (n = 1,005 and 1,658, respectively)
Influenza 
Season
Influenza 
type/
subtype
Time of sample 
collection
Cases Controls Crude VE Adjusted VEa
Vaccinated Unvaccinated Vaccinated Unvaccinated % (95% CI) % (95% CI)
2014/15
A + B
< 2 days after 
disease onset 34 115 59 306 −53.3 (−146.2 to 4.5) −41.8 (−144.5 to 17.7)
2–7 days after 
disease onset 25 133 62 271 17.8 (−36.6 to 50.6) 20.9 (−39.8 to 55.2)
A(H3N2)
< 2 days after 
disease onset 31 95 59 306
−69.3 (−176.9 to 
−3.5) −61.9 (−183.0 to 7.4)
2–7 days after 
disease onset 22 109 62 271 11.8 (−50.6 to 48.3) 14.7 (−153.7 to 52.7)
2015/16
A + B
< 2 days after 
disease onset 32 252 52 334 18.4 (−30.5 to 49.0) 22.8 (−29.1 to 53.9)
2–7 days after 
disease onset 79 422 79 408 3.3 (−35.9 to 31.2) 1.1 (−49.3 to 34.5)
A(H1N1)
pdm09b
< 2 days after 
disease onset 14 118 52 334 23.8 (−42.6 to 59.3) −47.8 (−192.4 to 25.3)
2–7 days after 
disease onset 24 187 79 408 33.7 (−8.1 to 59.3) −41.0 (−147.4 to 19.6)
Bb
< 2 days after 
disease onset 18 142 52 334 18.6 (−44.1 to 54.0) 26.7 (−37.1 to 60.8)
2–7 days after 
disease onset 53 235 79 408 −16.5 (−70.9 to 20.6) −18.5 (−88.8 to 25.6)
a Adjusted for age group, sex and calendar week for 2014/15, and adjusted for age group, sex, calendar week and underlying condition for 
2015/16.
b The 11 samples positive for influenza A(H1N1)pdm09 and influenza B in the 2015/16 season are included in the analysis of influenza A(H1N1)
pdm09 and influenza B.
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The low VE against influenza B in 2015/2016 in Israel 
differed from VE estimates from the US of 58% (95% 
CI: 40 to 70) against the Victoria lineage and 59% (95% 
CI: 45 to 69) against the Yamagata Lineage [32,38]. It 
also differed from VE estimate of around 50% among 
individuals less than 65 years of age in the UK, where, 
like in Israel, the Victoria lineage influenza B predomi-
nated [35]. Although, the VE of 76.5% (95% CI: 41.9 to 
90.5) for those 2 to 17 years of age in the UK can be 
attributed, at least in part, to the use of LAIV, the VE 
results of individuals between the ages of 18 and 64 in 
the UK who mostly received the TIV [35], suggest a dif-
ferent mechanism of protection.
The difference in VE results against influenza A(H1N1)
pdm09 between the two age groups examined in our 
study is interesting. The vaccine was moderately effec-
tive in adults, a finding consistent with studies from 
the UK and US [32,35]. However, the low VE against 
influenza A(H1N1)pdm09 in those less than 18 years 
of age in Israel differed from VE estimates in the same 
age group in those same countries [32,35]. Of particular 
note is the difference from the US study, which showed 
good VE among children receiving the injectable form 
of the influenza vaccine (while low VE estimates were 
found among children receiving the LAIV) [32]. It is 
worth noting the different vaccination rates among the 
adult and child controls in our study in 2015/16. While 
the vaccination rate among adult controls was 20.6%, 
it was 9.7% among control children (Table 4). By com-
parison, in the 2014/15 season the vaccination rates 
were similar in adult and children controls (18.6% and 
16.5%, respectively) (Table 3). The low rate of vacci-
nated controls in those less than 18 years of age may 
have resulted in reduced precision in VE determination.
Our study has several limitations. Our sample size was 
initially relatively small. However, we were able to add 
additional sentinel clinics for the 2015/16 season and 
increase the sample size by ca 40%. In addition, in 
both seasons we had a small number of participants 
in certain age groups. For this reason, we estimated 
VE for age strata of 18 years of age and over and less 
than 18 years of age. Further increasing our sample size 
in the future will allow stratification into additional age 
groups, particularly for seasons in which several influ-
enza types and subtypes co-circulate. For the 2014/15 
season we did not collect data regarding chronic medi-
cal conditions. However, this information was obtained 
during the 2015/16 season.
We used convenience sampling to select patients pre-
senting with ILI, similar to other studies in the field 
[3,18], which may have biased our sample. However, 
our sentinel clinics represented all seven districts in 
the country, and therefore, the sample likely repre-
sented larger Israeli society with respect to geography 
and population groups.
To evaluate whether our VE estimates might be influ-
enced by the time elapsed from disease onset to swab-
bing, we conducted a sensitivity analysis. Our analysis 
demonstrated substantial differences in VE between 
patients with samples obtained 0–1 days after disease 
onset compared with patients with samples collected 
2–7 days after disease onset. To account for these dif-
ferences, we adjusted for days from disease onset to 
swab in our VE estimation.
We did not have information regarding influenza vac-
cination in previous years among ILI patients. Thus, we 
were unable to measure VE considering previous vacci-
nation status. Influenza vaccination in preceding years 
may affect vaccine effectiveness results. Previous 
influenza vaccination has been associated with a nega-
tive effect on VE in several studies [24,28,39].
In conclusion, using data from a community-based 
influenza surveillance system in Israel, we estimated 
VE of inactivated influenza vaccine in the Israeli popu-
lation for the first time. Our study suggests that VE may 
vary by season, by influenza type and subtype as well 
as by age. Our results, and those of others, support the 
need for continued efforts of estimating influenza VE, 
both in outpatient and inpatient settings. These efforts 
are necessary in order to better understand the factors 
that affect influenza VE and to optimise vaccine compo-
sition and use. Timely VE estimates are of paramount 
importance for the yearly decision regarding influenza 
vaccine composition.
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